Alnylam: NHS OKs use in England of treatment for hereditary amyloidosis

Alnylam UK Limited, the leading RNA interference (RNAi) therapeutics company, today welcomed a decision from

the National Institute for Health and Care Excellence (NICE) recommending the use of ONPATTRO (patisiran) on the NHS in England for the

treatment of a progressive, life-threatening disease called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). Prior to this decision, there have been few treatment options available to patients with hATTR amyloidosis in England. Patisiran provides eligible patients suffering from this disease with a treatment option that addresses its underlying cause by reducing the production of an abnormal protein that damages nerves and organs across the body.

https://www.marketscreener.com/ALNYLAM-PHARMACEUTICALS-8322/news/Alnylam-Pharmaceuticals-First-in-class-lsquo-gene-silencing-therapy-approved-for-NHS-use-in-Engl-28874628/